Nuveen LLC Takes $1.72 Million Position in Trevi Therapeutics, Inc. $TRVI

Key Points

• Nuveen LLC has acquired a new position in Trevi Therapeutics, purchasing 273,620 shares valued at approximately $1,721,000, representing about 0.27% of the company.
• Trevi Therapeutics reported an EPS of (0.09) for the quarter, surpassing expectations, and analysts forecast an annual EPS of (0.49).
• Several analysts have provided updated ratings and target prices for Trevi Therapeutics, with the stock currently holding a consensus rating of "Buy" and an average target price of $20.11.

Nuveen LLC bought a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 273,620 shares of the company's stock, valued at approximately $1,721,000. Nuveen LLC owned about 0.27% of Trevi Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the company. Two Sigma Investments LP acquired a new stake in shares of Trevi Therapeutics during the fourth quarter valued at $560,000. Ameriprise Financial Inc. boosted its stake in Trevi Therapeutics by 187.0% in the 4th quarter. Ameriprise Financial Inc. now owns 96,784 shares of the company's stock worth $399,000 after buying an additional 63,067 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Trevi Therapeutics in the 1st quarter worth about $197,000. Renaissance Technologies LLC raised its holdings in shares of Trevi Therapeutics by 42.0% in the 4th quarter. Renaissance Technologies LLC now owns 100,400 shares of the company's stock worth $414,000 after purchasing an additional 29,700 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Trevi Therapeutics by 11.3% in the 4th quarter. Northern Trust Corp now owns 482,815 shares of the company's stock worth $1,989,000 after purchasing an additional 49,173 shares during the period. Institutional investors and hedge funds own 95.76% of the company's stock.

Trevi Therapeutics Stock Up 0.7%

Shares of TRVI traded up $0.05 during midday trading on Monday, reaching $7.26. The stock had a trading volume of 1,556,560 shares, compared to its average volume of 1,895,919. Trevi Therapeutics, Inc. has a 52 week low of $2.36 and a 52 week high of $8.78. The firm's 50 day moving average price is $6.95 and its 200-day moving average price is $6.32.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. On average, equities analysts predict that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on TRVI. D. Boral Capital reiterated a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Monday, June 2nd. Cantor Fitzgerald initiated coverage on Trevi Therapeutics in a report on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price objective on the stock. Needham & Company LLC decreased their target price on Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Morgan Stanley initiated coverage on Trevi Therapeutics in a research report on Thursday, August 21st. They set an "overweight" rating and a $18.00 price objective for the company. Finally, Wall Street Zen lowered Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, June 6th. Two research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat.com, Trevi Therapeutics has an average rating of "Buy" and a consensus price target of $20.11.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.